Crucell focuses on developing and marketing vaccines and antibodies against a range of infectious diseases. The Company currently has a product portfolio of vaccines against influenza, hepatitis A, hepatitis B and typhoid fever.

Vaccines play a vital role in protecting against disease and have contributed significantly to the improvement of global public health in the twentieth century. Smallpox was eradicated through the use of vaccines, and polio is well on its way to eradication. Significant developments include the introduction of combination vaccines and the development of new vaccine technologies that may advance vaccine development.

In this section, you will find information about Crucell’s vaccine products and comprehensive information about the diseases each of these vaccines is designed to prevent.

Crucell’s vaccines:

Paediatric:

• Quinvaxem^® - Fully liquid vaccine for protection against five childhood diseases
• Hepavax-Gene^® - Recombinant hepatitis B vaccine
• MoRu-Viraten^® - Vaccine for protection against measles and rubella (all age groups)
• Epaxal® Junior - Low dosage unique aluminum-free hepatitis A vaccine (0.25ml)

Travel and endemic:

• Epaxal^® - Unique aluminum-free hepatitis A vaccine
• Vivotif^® - Unique oral typhoid vaccine
• Dukoral^® - Internationally licensed oral vaccine with documented efficacy against diarrhea caused by cholera

Respiratory:

• Inflexal^® V – Virosomal adjuvanted influenza (all age groups)

Vaccine Discovery

Development Pipeline

Technology